Otsuka has claimed FDA approval for its IgA nephropathy (IgAN) therapy Voyxact, joining an increasingly crowded market and beating rival Vera Therapeutics to the punch. Anti-APRIL antibody Voyxact ...

A University of Toronto-led study has identified a possible biomarker linked to multiple sclerosis (MS) disease progression. The findings, validated in both mouse and in humans, could help to identify ...

Bree Walker has continued her super start to the Winter Olympic season by winning gold in the IBSF monobob World Cup race in Lillehammer. Walker set a track record of 53.86 seconds in the first run, ...

Equipes de Belém e Ananindeua representam o estado na final que reúne 376 participantes. Os vencedores serão anunciados nesta terça, 2, durante o Festival LED na Estação das Docas. Belém recebe, pela ...

A new FDA approval for a first-in-class drug has vaulted Otsuka into immunoglobulin A nephropathy (IgAN), an increasingly competitive kidney disease field targeted by multiple biopharma companies. The ...

IRVINE, Calif., Nov. 20, 2025 /PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotechnology company developing novel therapies for relapsed and refractory (r/r) B-cell malignancies, announced ...

At Vera Therapeutics, we began our journey with a single, driving question: what truly causes autoimmune kidney diseases like IgA nephropathy (IgAN), and how can we intervene at the source? As the ...

Povetacicept substantially reduced proteinuria with stable eGFR over 48 weeks in patients with IgAN or pMN, according to interim data from the phase 1/2 RUBY-3 trial. Povetacicept safely reduces ...

IgA nephropathy, the most common primary glomerulopathy worldwide, is a kidney disorder of B-cell origin characterized by mesangial accumulation of IgA-containing immune complexes. In at least 50% of ...

A San Francisco startup has raised more than $100 million for technology that could upend the global semiconductor industry—if it proves out. Founded by a protégé of investor Peter Thiel, Substrate ...

NEW YORK and WALTHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to ...